AKBA (Akebia Therapeutics, Inc.) is set to announce its Q2'26 results on July 30, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 48.85 million USD with EPS (earnings per share) anticipated at (0.04) USD. Learn more details a…
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. NASDAQ:AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 3 newly-hired employees options to purchase an aggregate of 125,600 shares of Akebia’s common st…
Akebia Therapeutics Price Target Maintained With a $6.00/Share by HC Wainwright & Co.
Akebia Therapeutics Inc NASDAQ:AKBA:
Akebia reported that a planned interim analysis of the VOICE trial met stopping criteria, showing non-inferiority and superiority of Vafseo on the primary composite endpoint (win odds 1.16, p=0.0016).Key Highlights:Original SEC Filing: Akebia Therapeutics, Inc. [ AKBA ] - 8-K - Jun. 30, 2026This is…
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimenPrimary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering CommitteeInterim analysis on primary…
Uniycive Therapeutics NASDAQ:UNCY said on Tuesday the U.S. Food and Drug Administration had declined to approve its drug to treat elevated phosphate levels in chronic kidney disease patients on dialysis, citing deficiencies at a third-party manufacturing facility.Shares of the company were down ove…
